Find Paid Clinical Trials in New Jersey

Paid Clinical Trials and Focus Groups

Find Paid Clinical Trials

Paid Clinical Trials in New Jersey

Top of Directory » All Locations » United States » New Jersey




  • Does Auricular Acupuncture Improve Tolerance to Electromyography (EMG) Testing?

    Condition:   Pain
    Intervention:   Other: auricular acupuncture
    Sponsor:   Kessler Foundation
    Recruiting - verified November 2009

  • Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

    Conditions:   Squamous Cell Cancer;   Head and Neck Cancer
    Intervention:   Drug: Temsirolimus + Weekly Paclitaxel + Carboplatin
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   NATL COMP CA NETWORK;   Wyeth
    Recruiting - verified November 2009

  • BIBF 1120 or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

    Conditions:   Ovarian Neoplasms;   Peritoneal Neoplasms
    Interventions:   Drug: BIBF 1120;   Drug: Placebo
    Sponsor:   Boehringer Ingelheim Pharmaceuticals
    Not yet recruiting - verified November 2009

  • Bisacodyl Use in the Post-operative Care of Obstetrical/Gynecological (OB/GYN) Patients

    Conditions:   Postoperative Nausea and Vomiting;   Abdominal Pain
    Interventions:   Drug: Bisacodyl;   Drug: placebo
    Sponsor:   The Cooper Health System
    Recruiting - verified November 2009

  • Tetradecanoylphorbol Acetate, Dexamethasone, and Choline Magnesium Trisalicylate in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

    Condition:   Leukemia
    Interventions:   Drug: choline magnesium trisalicylate;   Drug: dexamethasone;   Drug: tetradecanoylphorbol acetate;   Other: laboratory biomarker analysis
    Sponsors:   Cancer Institute of New Jersey;   National Cancer Institute (NCI)
    Recruiting - verified October 2009

  • A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

    Condition:   Pulmonary Disease, Chronic Obstructive
    Interventions:   Drug: GW642444 Inhalation Powder;   Drug: FF/GW642444 Inhalation Powder
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

    Conditions:   Proctitis;   Proctosigmoiditis
    Interventions:   Drug: Budesonide;   Drug: Placebo
    Sponsor:   Salix Pharmaceuticals
    Not yet recruiting - verified November 2009

  • Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

    Conditions:   Proctitis;   Proctosigmoiditis
    Interventions:   Drug: Budesonide;   Drug: Placebo
    Sponsor:   Salix Pharmaceuticals
    Not yet recruiting - verified November 2009

  • A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: tocilizumab;   Drug: tocilizumab;   Drug: methotrexate
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009

  • The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

    Condition:   Onychomycosis
    Interventions:   Drug: IDP-108;   Drug: Vehicle
    Sponsor:   Dow Pharmaceutical Sciences
    Not yet recruiting - verified November 2009

  • A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies

    Condition:   Lymphoid Malignancies
    Intervention:   Drug: HGS1029
    Sponsor:   Human Genome Sciences
    Recruiting - verified November 2009

  • Study of A3309 in Patients With Chronic Idiopathic Constipation

    Conditions:   Constipation;   Chronic Constipation
    Intervention:   Drug: A3309
    Sponsor:   Albireo
    Recruiting - verified November 2009

  • Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

    Condition:   Colorectal Cancer
    Interventions:   Biological: bevacizumab;   Drug: XELOX regimen;   Drug: capecitabine;   Drug: hydroxychloroquine;   Drug: oxaliplatin;   Other: laboratory biomarker analysis
    Sponsors:   Cancer Institute of New Jersey;   National Cancer Institute (NCI)
    Recruiting - verified August 2009

  • Study to Compare Gastric Inhibition of Two Proton Pump Inhibitors (CL2008-18)

    Condition:   Human Experimentation
    Interventions:   Drug: Zegerid;   Drug: Prevacid;   Other: No Treatment
    Sponsor:   Schering-Plough
    Recruiting - verified October 2009

  • Study of Bone Marrow and Blood Samples in Patients With Untreated Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Enrolled on Clinical Trial CALGB-9621 or CALGB-9720

    Condition:   Leukemia
    Intervention:   Other: laboratory biomarker analysis
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial

    Condition:   Leukemia
    Interventions:   Genetic: DNA analysis;   Genetic: Southern blotting;   Genetic: cytogenetic analysis;   Genetic: polymerase chain reaction
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia

    Condition:   Leukemia
    Interventions:   Genetic: fluorescence in situ hybridization;   Genetic: mutation analysis;   Genetic: nucleic acid sequencing;   Genetic: polymerase chain reaction;   Genetic: western blotting;   Other: flow cytometry;   Other: laboratory biomarker analysis
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis

    Condition:   Ulcerative Colitis
    Interventions:   Drug: Asacol (mesalamine), High Dose;   Drug: Asacol (mesalamine), Low Dose
    Sponsor:   Procter and Gamble
    Recruiting - verified October 2009

  • Follicle Stimulating Hormone (FSH) Receptor Polymorphisms in In-Vitro Fertilization Cycles.

    Condition:   Infertility
    Intervention:  
    Sponsors:   University Reproductive Associates;   Ferring Pharmaceuticals
    Recruiting - verified October 2009

  • Single Injection of RGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain

    Condition:   Abdominal Pain Upper
    Interventions:   Drug: RGN475/SAR164877;   Drug: Placebo
    Sponsors:   Sanofi-Aventis;   Regeneron Pharmaceuticals
    Not yet recruiting - verified October 2009

  • Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain

    Condition:   Back Pain
    Interventions:   Drug: REGN475/SAR164877;   Drug: Placebo
    Sponsors:   Sanofi-Aventis;   Regeneron Pharmaceuticals
    Not yet recruiting - verified October 2009

  • Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor

    Condition:   Neoplasms, Malignant
    Interventions:   Drug: cabazitaxel (XRP6258);   Drug: gemcitabine;   Drug: midazolam
    Sponsor:   Sanofi-Aventis
    Not yet recruiting - verified October 2009

  • Single Dose Safety, Tolerance and Pharmacokinetic Study in Healthy Volunteers Undergoing Contrast-enhanced Abdominal Computed Tomography (CT)

    Condition:   Healthy
    Interventions:   Drug: GE-145 (AN113111) Injection;   Drug: Visipaque (iodixanol) Injection
    Sponsors:   GE Healthcare;   Medpace, Inc.;   i3 Statprobe
    Recruiting - verified October 2009

  • Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

    Conditions:   Lymphoma;   Lymphoproliferative Disorder
    Interventions:   Other: biologic sample preservation procedure;   Other: informational intervention
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Safety and Efficacy of Direct Blood Volume Measurement in the Treatment of Heart Failure

    Condition:   Heart Failure
    Interventions:   Other: Daxor Blood Volume Analysis;   Other: Clinical volume status assessment
    Sponsors:   New York University School of Medicine;   Daxor Corporation
    Not yet recruiting - verified October 2009

  • Dexmedetomidine Versus Propofol in Vitreoretinal Surgery

    Condition:   Ambulatory Surgery
    Interventions:   Drug: Dexmedetomidine infusion;   Drug: propofol
    Sponsor:   University of Medicine and Dentistry New Jersey
    Recruiting - verified October 2009

  • The Effects of Different Ventilator Strategies on Inflammation and Injury in Normal Lungs

    Condition:   Acute Respiratory Distress Syndrome
    Intervention:   Other: Ventilator settings
    Sponsor:   University of Medicine and Dentistry New Jersey
    Recruiting - verified October 2009

  • A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy

    Condition:   Pregnancy Prevention
    Intervention:   Drug: DR-103
    Sponsor:   Teva Women's Health
    Recruiting - verified October 2009

  • TAXUS Libertē Post Approval Study

    Condition:   Coronary Artery Disease
    Interventions:   Device: TAXUS Liberté Paclitaxel-Eluting Coronary Stent;   Drug: prasugrel;   Drug: placebo;   Drug: aspirin
    Sponsors:   Boston Scientific Corporation;   Eli Lilly and Company;   Daiichi Sankyo Inc.
    Not yet recruiting - verified November 2009

  • Donor Stem Cell Transplant After Total-Body Irradiation in Treating Patients With Relapsed or Refractory Hematologic Cancer or Acute Myeloid Leukemia or Acute Lymphocytic Leukemia in Complete Remission

    Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: cellular immunotherapy;   Biological: donor lymphocytes;   Biological: filgrastim;   Biological: pegfilgrastim;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsors:   Cancer Institute of New Jersey;   National Cancer Institute (NCI)
    Recruiting - verified October 2009

  • The Women's HIV SeroIncidence Study (ISIS)

    Condition:   HIV Infections
    Intervention:  
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified June 2009

  • 6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes

    Condition:   Type 1 Diabetes Mellitus
    Interventions:   Drug: INSULIN GLARGINE (HOE901);   Drug: Neutral Protamine Hagedorn (NPH) insulin
    Sponsor:   Sanofi-Aventis
    Recruiting - verified November 2009

  • Dose Ranging Study of Celivarone With Amiodarone as Calibrator for the Prevention of Implantable Cardioverter Defibrillator (ICD) Interventions or Death

    Condition:   Arrhythmia Prophylaxis
    Interventions:   Drug: Celivarone (SSR149744);   Drug: amiodarone;   Drug: placebo
    Sponsor:   Sanofi-Aventis
    Recruiting - verified November 2009

  • Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth

    Conditions:   HIV Infections;   H1N1 Influenza Virus
    Intervention:   Biological: Influenza A (H1N1) 2009 monovalent vaccine
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Not yet recruiting - verified October 2009

  • Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women

    Conditions:   HIV Infections;   H1N1 Influenza Virus
    Intervention:   Biological: Influenza A (H1N1) monovalent vaccine
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified October 2009

  • A Study of Tocilizumab in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis

    Condition:   Juvenile Idiopathic Arthritis
    Interventions:   Drug: tocilizumab;   Drug: tocilizumab;   Drug: tocilizumab;   Drug: placebo;   Drug: NSAIDs, corticosteroids, methotrexate
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009

  • Study of the Effects of SCH 527123 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (Protocol No. P05575)

    Condition:   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: SCH 527123;   Drug: Placebo
    Sponsor:   Schering-Plough
    Recruiting - verified November 2009

  • Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence

    Condition:   Keloids
    Interventions:   Drug: QAX576;   Drug: QAX576 placebo
    Sponsor:   Novartis Pharmaceuticals
    Recruiting - verified November 2009

  • Sugammadex Hypersensitivity Study (Study P06042)

    Condition:   Hypersensitivity
    Interventions:   Drug: Sugammadex 4 mg/kg;   Drug: Sugammadex 16 mg/kg;   Drug: Placebo
    Sponsor:   Schering-Plough
    Recruiting - verified October 2009

  • Effects of the V1a Agonist FE 202158 in Patients With Septic Shock

    Condition:   Septic Shock
    Interventions:   Drug: FE 202158;   Drug: Sodium Chloride
    Sponsor:   Ferring Pharmaceuticals
    Not yet recruiting - verified October 2009

  • Carboplatin and Paclitaxel Combined With Cetuximab and/or Cixutumumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

    Condition:   Lung Cancer
    Interventions:   Biological: cetuximab;   Biological: cixutumumab;   Drug: carboplatin;   Drug: paclitaxel
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain

    Conditions:   Pain;   Back Pain;   Low Back Pain;   Back Pain With Radiation
    Interventions:   Drug: Oxycodone IR;   Drug: NUCYNTA
    Sponsors:   Ortho-McNeil Janssen Scientific Affairs, LLC;   Grünenthal
    Recruiting - verified October 2009

  • Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older

    Condition:   Influenza Infection
    Interventions:   Biological: GSK2340273A;   Biological: Saline placebo;   Biological: GSK2340274A
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • Treatment of Androgenetic Alopecia in Females, 9 Beam

    Conditions:   Androgenetic Alopecia;   Hair Loss;   Female Pattern Baldness
    Interventions:   Device: HairMax LaserComb;   Device: Sham Device
    Sponsor:   Lexington International, LLC
    Recruiting - verified November 2009

  • Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding

    Condition:   Breast Cancer
    Interventions:   Drug: BIIB021;   Drug: BIIB021;   Drug: exemestane (Aromisin)
    Sponsor:   Biogen Idec
    Recruiting - verified November 2009

  • Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older

    Condition:   Influenza Infection
    Interventions:   Biological: GSK2340273A;   Biological: GSK2340274A
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • 24-Week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50

    Condition:   Type 2 Diabetes Mellitus
    Interventions:   Drug: Lixisenatide (AVE0010);   Drug: Sitagliptin
    Sponsor:   Sanofi-Aventis
    Recruiting - verified November 2009

  • A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia

    Condition:   Schizophrenia
    Interventions:   Drug: PF-03463275;   Drug: Placebo
    Sponsor:   Pfizer
    Not yet recruiting - verified November 2009

  • Hematuria Evaluation Trial for Subjects With Microscopic or Gross Hematuria to Determine the Absence or Presence of Bladder Cancer

    Condition:   Microscopic or Gross Hematuria
    Intervention:  
    Sponsor:   Predictive Biosciences
    Recruiting - verified November 2009

  • 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine

    Condition:   Type 2 Diabetes Mellitus
    Interventions:   Drug: lixisenatide (AVE0010);   Drug: placebo;   Drug: insulin glargine (HOE901)
    Sponsor:   Sanofi-Aventis
    Recruiting - verified November 2009

    • Menu
    Find Paid Clinical Trials